Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
/ 8 items
#NTLA↓
FDA Lifts Hold on Intellia’s Phase 3 Gene-Editing Trial for Deadly Heart Disease
Intellia Therapeutics gets FDA approval to resume its Phase 3 trial for nexiguran ziclumeran, a gene-editing treatment for ATTR-CM heart disease, boosting shares by 6%.
Intellia Shares Jump After FDA Lifts Clinical Hold on Gene Therapy Trial
Intellia Therapeutics’ stock rises as the FDA clears a Phase 3 trial for its gene therapy, nexiguran ziclumeran, for a rare genetic disease.
Intellia Therapeutics Shares Plunge 29% After FDA Pauses Key Gene Therapy Trials
Intellia Therapeutics (NTLA) shares fell 29% premarket after the FDA paused two late-stage gene-editing trials following a patient death linked to liver complications.
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.
Intellia Therapeutics Stock Plunges on FDA Clinical Hold
Intellia Therapeutics (NTLA) shares drop 15% after FDA halts late-stage gene therapy trials following serious liver safety concerns in patient.